Medical cannabinoids in children and adolescents: A systematic review

Pediatrics

Volumn 140, Issue 5, 2017, Pages

  Wong, Shane Shucheng ^a   Wilens, Timothy E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEDICAL CANNABIS; CANNABINOID;

ADOLESCENCE; ADOLESCENT; ANXIETY; CASE STUDY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILD; CHILD CARE; DRUG INDICATION; DRUG USE; EPILEPSY; EVIDENCE BASED MEDICINE; GILLES DE LA TOURETTE SYNDROME; HEALTH SURVEY; HUMAN; META ANALYSIS; NEUROPATHIC PAIN; PARENT; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SLEEP; SOCIAL PSYCHOLOGY; SPASTICITY; SYSTEMATIC REVIEW; CANNABIS SMOKING; CASE REPORT; CHEMICALLY INDUCED; DRUG THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; NAUSEA; PROCEDURES; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TOURETTE SYNDROME; VOMITING;

ADOLESCENT; CANNABINOIDS; CHILD; DRUG THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EPILEPSY; HUMANS; MARIJUANA SMOKING; MEDICAL MARIJUANA; NAUSEA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOURETTE SYNDROME; VOMITING;

EID: 85033571909     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2017-1818     Document Type: Review

References (66)

1. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360
2. Solvay Pharmaceuticals, Inc. Marinol. 2004. Available at: https://www.fda.gov/ohrms/dockets/dockets/05n0479/05N-0479-emc0004-04.pdf. Accessed January 28, 2017
3. Valeant Pharmaceuticals International. Cesamet. 2006. Available at: https://www.accessdata. fda.gov/drugsatfda-docs/label/2006/018677s011lbl.pdf. Accessed January 28, 2017
4. National Conference of State Legislatures. State medical marijuana laws. 2016. Available at: www. ncsl. org/research/health/state-medicalmarijuana-laws. aspx. Accessed January 28, 2017
5. Ammerman S, Ryan S, Adelman WP, et al; Committee on Substance Abuse, Committee on Adolescence; Committee on Substance Abuse Committee on Adolescence. The impact of marijuana policies on youth: clinical, research, and legal update. Pediatrics. 2015;135(3): 584-587
6. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-Analyses: The PRISMA statement. PLoS Med. 2009;6(7):e1000097
7. Elder JJ, Knoderer HM. Characterization of dronabinol usage in a pediatric oncology population. J Pediatr Pharmacol Ther. 2015;20(6):462-467
8. Abrahamov A, Abrahamov A, Mechoulam R. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci. 1995;56(23-24):2097-2102
9. Chan HS, Correia JA, MacLeod SM. Nabilone versus prochlorperazine for control of cancer chemotherapyinduced emesis in children: A doubleblind, crossover trial. Pediatrics. 1987;79(6):946-952
10. Dalzell AM, Bartlett H, Lilleyman JS. Nabilone: An alternative antiemetic for cancer chemotherapy. Arch Dis Child. 1986;61(5):502-505
11. Ekert H, Waters KD, Jurk IH, Mobilia J, Loughnan P. Amelioration of cancer chemotherapyinduced nausea and vomiting by delta-9-Tetrahydrocannabinol. Med J Aust. 1979;2(12):657-659
12. Devinsky O, Cross JH, Laux L, et al; Cannabidiol in Dravet Syndrome Study Group. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21): 2011-2020
13. Gofshteyn JS, Wilfong A, Devinsky O, et al. Cannabidiol as a potential treatment for febrile infection-related epilepsy syndrome (FIRES) in the acute and chronic phases. J Child Neurol. 2017;32(1):35-40
14. Kaplan EH, Offermann EA, Sievers JW, Comi AM. Cannabidiol treatment for refractory seizures in Sturge-Weber syndrome. Pediatr Neurol. 2017;71: 18-23.e2
15. Treat L, Chapman KE, Colborn KL, Knupp KG. Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients. Epilepsia. 2017;58(1):123-127
16. Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatmentresistant epilepsy: An open-label interventional trial. Lancet Neurol. 2016;15(3):270-278
17. Tzadok M, Uliel-Siboni S, Linder I, et al. CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience. Seizure. 2016;35:41-44
18. Hussain SA, Zhou R, Jacobson C, et al. Perceived efficacy of cannabidiolenriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy Behav. 2015;47:138-141
19. Press CA, Knupp KG, Chapman KE. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav. 2015;45:49-52
20. Saade D, Joshi C. Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: A case report. Pediatr Neurol. 2015;52(5):544-547
21. Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatmentresistant epilepsy. Epilepsy Behav. 2013;29(3):574-577
22. L orenz R. On the application of cannabis in paediatrics and epileptology. Neuroendocrinol Lett. 2004;25(1-2):40-44
23. Rudich Z, Stinson J, Jeavons M, Brown SC. Treatment of chronic intractable neuropathic pain with dronabinol: case report of two adolescents. Pain Res Manag. 2003;8(4):221-224
24. Shannon S, Opila-Lehman J. Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: A case report. Perm J. 2016;20(4):108-111
25. Kuhlen M, Hoell JI, Gagnon G, et al. Effective treatment of spasticity using dronabinol in pediatric palliative care. Eur J Paediatr Neurol. 2016;20(6):898-903
26. L orenz R. A casuistic rationale for the treatment of spastic and myocloni in a childhood neurodegenerative disease: neuronal ceroid lipofuscinosis of the type Jansky-Bielschowsky. Neuroendocrinol Lett. 2002;23(5-6):387-390
27. Hasan A, Rothenberger A, Mönchau A, Wobrock T, Falkai P, Roessner V. Oral delta 9-Tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: A case report. J Clin Psychopharmacol. 2010;30(2):190-192
28. Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev. 2015;(11):CD009464
29. National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017
30. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and meta-Analysis. JAMA. 2015;313(24):2456-2473
31. Andreae MH, Carter GM, Shaparin N, et al. Inhaled cannabis for chronic neuropathic pain: A meta-Analysis of individual patient data. J Pain. 2015;16(12):1221-1232
32. Jetly R, Heber A, Fraser G, Boisvert D. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-Associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015;51:585-588
33. Wilkinson ST, Stefanovics E, Rosenheck RA. Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. J Clin Psychiatry. 2015;76(9):1174-1180
34. Möller-Vahl KR, Schneider U, Prevedel H, et al. Delta 9-Tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: A 6-week randomized trial. J Clin Psychiatry. 2003;64(4):459-465
35. Möller-Vahl KR, Schneider U, Koblenz A, et al. Treatment of Tourettes syndrome with 9-Tetrahydrocannabinol (THC): A randomized crossover trial. Pharmacopsychiatry. 2002;35(2): 57-61
36. Wang T, Collet JP, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: A systematic review. CMAJ. 2008;178(13):1669-1678
37. Claudet I, Le Breton M, Bréhin C, Franchitto N. A 10-year review of cannabis exposure in children under 3-years of age: do we need a more global approach? Eur J Pediatr. 2017;176(4):553-556
38. Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol. 2013;64(1):21-47
39. Burns HD, Van Laere K, Sanabria-Bohórquez S, et al. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci USA. 2007;104(23):9800-9805
40. L isdahl KM, Gilbart ER, Wright NE, Shollenbarger S. Dare to delay? The impacts of adolescent alcohol and marijuana use onset on cognition, brain structure, and function. Front Psychiatry. 2013;4:53
41. Jacobsen LK, Mencl WE, Westerveld M, Pugh KR. Impact of cannabis use on brain function in adolescents. Ann N Y Acad Sci. 2004;1021(1):384-390
42. Jacobsen LK, Pugh KR, Constable RT, Westerveld M, Mencl WE. Functional correlates of verbal memory deficits emerging during nicotine withdrawal in abstinent adolescent cannabis users. Biol Psychiatry. 2007;61(1):31-40
43. Medina KL, McQueeny T, Nagel BJ, Hanson KL, Yang TT, Tapert SF. Prefrontal cortex morphometry in abstinent adolescent marijuana users: subtle gender effects. Addict Biol. 2009;14(4):457-468
44. Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA. 2012;109(40):E2657-E2664
45. Jackson NJ, Isen JD, Khoddam R, et al. Impact of adolescent marijuana use on intelligence: results from two longitudinal twin studies. Proc Natl Acad Sci USA. 2016;113(5):E500-E508
46. Rogeberg O. Correlations between cannabis use and IQ change in the Dunedin cohort are consistent with confounding from socioeconomic status. Proc Natl Acad Sci USA. 2013;110(11):4251-4254
47. Solowij N, Jones KA, Rozman ME, et al. Verbal learning and memory in adolescent cannabis users, alcohol users and non-users. Psychopharmacology (Berl). 2011;216(1):131-144
48. Nguyen-Louie TT, Castro N, Matt GE, Squeglia LM, Brumback T, Tapert SF. Effects of emerging alcohol and marijuana use behaviors on adolescents neuropsychological functioning over four years. J Stud Alcohol Drugs. 2015;76(5):738-748
49. Tapert SF, Granholm E, Leedy NG, Brown SA. Substance use and withdrawal: neuropsychological functioning over 8 years in youth. J Int Neuropsychol Soc. 2002;8(7):873-883
50. Ehrenreich H, Rinn T, Kunert HJ, et al. Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology (Berl). 1999;142(3):295-301
51. Fontes MA, Bolla KI, Cunha PJ, et al. Cannabis use before age 15 and subsequent executive functioning. Br J Psychiatry. 2011;198(6):442-447
52. Pope HG Jr, Gruber AJ, Hudson JI, Cohane G, Huestis MA, Yurgelun-Todd D. Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend. 2003;69(3):303-310
53. Schoedel KA, Chen N, Hilliard A, et al. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Hum Psychopharmacol. 2011;26(3):224-236
54. L opez-Quintero C, Pérez de los Cobos J, Hasin DS, et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2011;115(1-2):120-130
55. Anthony JC. The epidemiology of cannabis dependence. In: Roffman RA, Stephens RS, eds. Cannabis Dependence: Its Nature, Consequences and Treatment. Cambridge, United Kingdom: Cambridge University Press; 2006;58-105
56. Wagner FA, Anthony JC. From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropsychopharmacology. 2002;26(4):479-488
57. Lynskey MT, Heath AC, Bucholz KK, et al. Escalation of drug use in early-onset cannabis users vs co-Twin controls. JAMA. 2003;289(4):427-433
58. Hayatbakhsh MR, Najman JM, Jamrozik K, Mamun AA, Alati R, Bor W. Cannabis and anxiety and depression in young adults: A large prospective study. J Am Acad Child Adolesc Psychiatry. 2007;46(3):408-417
59. Feingold D, Weiser M, Rehm J, Lev-Ran S. The association between cannabis use and mood disorders: A longitudinal study. J Affect Disord. 2015;172:211-218
60. L ynskey MT, Glowinski AL, Todorov AA, et al. Major depressive disorder, suicidal ideation, and suicide attempt in twins discordant for cannabis dependence and early-onset cannabis use. Arch Gen Psychiatry. 2004;61(10):1026-1032
61. Pedersen W. Does cannabis use lead to depression and suicidal behaviours? A population-based longitudinal study. Acta Psychiatr Scand. 2008;118(5):395-403
62. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002;325(7374):1212-1213
63. Bechtold J, Hipwell A, Lewis DA, Loeber R, Pardini D. Concurrent and sustained cumulative effects of adolescent marijuana use on subclinical psychotic symptoms. Am J Psychiatry. 2016;173(8):781-789
64. L ynskey M, Hall W. The effects of adolescent cannabis use on educational attainment: A review. Addiction. 2000;95(11):1621-1630
65. Monshouwer K, VAN Dorsselaer S, Verdurmen J, Bogt TT, DE Graaf R, Vollebergh W. Cannabis use and mental health in secondary school children. Findings from a Dutch survey. Br J Psychiatry. 2006;188(2):148-153
66. Fergusson DM, Boden JM. Cannabis use and later life outcomes. Addiction. 2008;103(6):969-976; discussion 977-978